Volume 596 Issue 7871, 12 August 2021
Article | 09 June 2021 | Open Access
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Analysis of the immunogenicity of the Ad26.COV2.S vaccine against the B1.351 and P.1 SARS-CoV-2 variants of concern shows reduced neutralization antibody titres, but comparable T cell responses and antibody-dependent effector functions.
Galit Alter, Jingyou Yu, Dan H. Barouch